Frontlight ResearchEarly access
Taking people in ItalyPhase 2
Tests foetal neural stem cells in people with progressive multiple sclerosis
Tests injected foetal stem cells against a sham procedure in adults with progressive multiple sclerosis.
Key facts
- Who runs it
- Ospedale San Raffaele S.r.l.
- Where
- Bergamo, Como, Milan, Monza, and Pavia, ItalySee the 7 sites
- Trial code
- Registry title
- Foetal neural stem cells transplantation in progressive multiple sclerosis
- Status
- Recruiting
- Phase
- Phase 2
- People taking part
- 86 people, planned
- Started
- 20 Nov 2025
- Expected to end
- 6 Feb 2028
- Type of study
- Interventional
- Record updated
- 19 October 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with progressive multiple sclerosis who have not responded to, could not tolerate, or could not use approved treatments.
- Age
- 18 to 65 years
- Sex
- Women and men can join.
- Disease stage
- Progressive multiple sclerosis (2017 revised McDonald criteria), with an EDSS score between 3.0 and 8.0 at screening.
- Earlier treatment
- Approved treatments must have failed (confirmed progression despite at least two years of treatment), caused side effects that stopped the drug, or not been possible to use. Some earlier medicines need a pause first, for example corticosteroids 1 months, cladribine 2 years, alemtuzumab 4 years.
Main reasons for not taking part
- Cannot complete an MRI scan
- Hepatitis B or C infection at screening
- Clinical relapse or signs of inflammatory activity on scans in the two years before screening
- History of HIV infection
- Pregnant, breastfeeding or planning pregnancy during the trial
The registry criteria, word for word
Show all 20 criteriaShow less
Who can take part
- Participant is willing and able to give informed consent for participation in the trial
- Male and Female, between 18 and 65 years inclusive
- Diagnosed with PMS (as per the 2017 revised McDonald criteria1)
- EDSS between 3.0 and 8.0 at screening
- Failure (confirmed disease progression despite an adequate duration of treatment of at least two years), intolerance (occurrence of AEs resulting in the discontinuation of the drug as per clinical practice), or ineligibility to the approved therapies according to the disease course
- Ability to take oral medication and be willing to adhere to the study procedures
- For females of reproductive potential: use of highly effective contraception for at least 1 month prior to screening and agreement to use such a method during study participation
- For males of reproductive potential: use of an effective strategy of birth control and abstention from sperm donation, for the entire duration of the study
Who cannot take part
- Use of prior/concomitant therapy in the following time frame (no wash out is required for interferon beta, glatiramer acetate or dimethyl fumarate treatments although use is not permitted on or after Day 1): a) Siponimod, fingolimod, natalizumab 3 months b) Corticosteroids, 1 months c) Teriflunomide no time restriction if accelerated elimination procedure is done; in case of no accelerated elimination procedure, 3 months d) Mildly to moderately immunosuppressive /chemotherapeutic medications such azathioprine, mycophenolate mofetil, and methotrexate, 3 months e) Highly immunosuppressive/chemotherapeutic medications, cyclophosphamide, 6 months f) Ocrelizumab and rituximab, 6 months g) Cladribine, 2 years from first pills h) Alemtuzumab, 4 years from last infusion i) Other MS-disease-modifying therapies 5 half-lives or until end of pharmacodynamics activity, whichever is longer
- Persistent chronic or active recurring infection requiring treatment with antibiotics, antivirals, or antifungals
- History of active or latent tuberculosis (unless the participant has completed a full course of anti-tuberculosis therapy or it is documented by a specialist that the participant has been adequately treated and can begin treatment with an immunosuppressive agent)
- Inability to complete the MRI scan (e.g., cardiac pacemaker, metallic implants in high-risk areas, gadolinium intolerance, or history of claustrophobia that would prevent completion of all protocol scheduled MRI)
- Participants at risk of developing or having reactivation of hepatitis: results at screening for serological markers for hepatitis B and C indicating acute or chronic infection
- Any other conditions or diagnosis, both physical or psychological, or physical exam finding that would adversely affect participation or Investigational Medicinal Product (IMP) administration in this study, as judged by the Investigator
- Known allergic reactions, intolerance, or contraindications to any medication, treatments and procedures that will be used in the study
- History of infection with human immunodeficiency virus (HIV)
- Female participant who is pregnant, lactating or planning pregnancy during the course of the trial, or of childbearing age who are not willing to use a contraceptive method effective for the entire duration of the study
- Male participant of reproductive potential who is not willing to use an effective strategy of birth control and/or to abstain from sperm donation
- The participation in the study is also not permitted to employees of the investigational site with direct involvement in the study or in other studies under the direction of that Investigator, as well as family members of the employees or the Investigator
- Clinical relapse and/or radiological features suggestive of inflammatory activity in the two years preceding the screening
Where in Italy
- Azienda Socio Sanitaria Territoriale Papa Giovanni XXIIIBergamo, ItalyTaking people
- Congregazione Delle Suore Infermiere Dell'AddolorataComo, ItalyTaking people
- ASST Grande Ospedale Metropolitano NiguardaMilan, ItalyTaking people
- IRCCS Foundation Istituto Neurologico Carlo BestaMilan, ItalyTaking people
- Ospedale San Raffaele S.r.l.Milan, ItalyTaking people
- Fondazione IRCCS San Gerardo dei TintoriMonza, ItalyTaking people
- Fondazione Istituto Neurologico Nazionale Casimiro MondinoPavia, ItalyTaking people
About the trial
What the trial wants to find out
To evaluate the therapeutic efficacy of hfNPCs (two intrathecal (IT) administrations of 200 x 10^6±10% cells, six months apart from each other) compared to sham procedure in patients with PMS.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorData and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).
- Official title
- A phase 2, randomized, patient and assessor blind, multicentre study comparing foetal neural stem cells transplantation to sham procedure in progressive multiple sclerosis (STEMS2)
- Plain-language title
- Tests foetal neural stem cells in people with progressive multiple sclerosisGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 9 November 2026.
- Record updated
- 19 October 2026